Our Current Trials

Condition Trial Name Sponsor
Solid Tumors 1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors Mirati Therapeutics, Inc.
Rectal Cancer 19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma Memorial Sloan Kettering Cancer Center
Breast Cancer ACE-Breast-03: ARX788 in HER2-positive, Metastatic Breast Cancer Subjects Previously Treated with T-DXd Ambrx, Inc.
Chronic Myelogenous Leukemia ASC2ESCALATE: Asciminib Monotherapy as First or Second Line Treatment Novartis Pharmaceuticals
Breast Cancer ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer Gilead Sciences
Breast Cancer ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer Gilead Sciences, Inc.
Cachexia in Colorectal or Pancreatic Cancer AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy AVEO Pharmaceuticals, Inc.
Colon Cancer AZUR-2: Perioperative Dostarlimab in Patients with dMMR/MSI-H Resectable Colon Cancer GlaxoSmithKline
Solid Tumors BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors Boehringer Ingelheim
HER2 Expressing Solid Tumors BL-M07D1-ST-101: Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors SystImmune Inc.
Breast Cancer BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer BriaCell Therapeutics Corporation
Solid Tumor or Lymphoma CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas CStone Pharmaceuticals
Non-Small Cell Lung Cancer CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform Elephas Biosciences Corporation
Prostate Cancer Debio 4228-201: Study of Extended Release GnRH in Newly Diagnosed Locally Advanced or Metastatic Prostate Cancer Debiopharm International SA
Non-Small Cell Lung Cancer EIK1001-005: EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer Eikon Therapeutics
Breast Cancer ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor Stemline Therapeutics, Inc.
Diffuse Large B-Cell Lymphoma EPCORE DLBCL-2: Epcoritamab in Combination with R-CHOP vs R-CHOP Alone as First Line Treatment AbbVie
Diffuse Large B-Cell Lymphoma or Follicular Lymphoma EPCORE: Epcoritamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Follicular Lymphoma AbbVie Inc.
Central Nervous System Cancer F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy Fore Biotherapeutics
Solid Tumors F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors Fore Biotherapeutics
Breast Cancer First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer Regor Pharmaceuticals Inc.
Gastric or Gastroesophageal Junction Cancer GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma AstraZeneca
Non-Small Cell Lung Cancer KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation Mirati Therapeutics, Inc.
Colon or Rectal Cancer LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash Lutris Pharma Ltd.
Follicular Lymphoma or Marginal Zone Lymphoma MAHOGANY: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/​Refractory Follicular or Marginal Zone Lymphoma BeiGene, Ltd.
Non-Hodgkin Lymphoma MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies Genentech, Inc.
Hyperkalemia/Chronic Kidney Disease NYH-01: Hyperkalemia/Chronic Kidney Disease Relypsa
Breast Cancer OPERA-01: OP-1250 (palazestrant) in ER-Positive and HER2-Negative Metastatic Breast Cancer Previously Treated with a CDK4/6 Inhibitor Olema Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer Regeneron Pharmaceuticals
ITP, wAIHA, CAD RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias Alpine Immune Sciences, Inc.
Breast Cancer SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression AstraZeneca
Solid Tumors STELLAR-009: Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab Exelixis
Head and Neck Squamous Cell Carcinoma STELLAR-305: Zanzalintinib in Combination with Pembrolizumab as First Line Therapy for Recurrent or Metastatic Disease Exelixis
Non-Small Cell Lung Cancer TROPION-Lung07: Datopotamab Deruxtecan Combinations vs Standard Chemo/Immunotherapy for the First Line Treatment of Non-Squamous Non-Small Cell Lung Cancer Daiichi Sankyo, Inc.
Cancer Diagnosis [Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients Memorial Sloan Kettering Cancer Center
Various Indications [Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) Precision for Medicine
Solid Tumors [Sample Collection] Collection and Distribution of Biofluids for Research Purposes Bluestar Genomics
Solid Tumors [Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) Exact Sciences Thrive LLC
Various Indications [Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022) MT Group
Various Indications [Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) SERATRIALS, LLC.
Solid Tumors [Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening Freenome Holdings Inc.